deltatrials
Completed PHASE3 NCT00811798

Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Subjects.

Sponsor: GlaxoSmithKline

Conditions Infections, Papillomavirus
Interventions Cervarix
Updated 8 times since 2017 Last updated: Sep 23, 2016 Started: May 31, 2009 Primary completion: Sep 30, 2010 Completion: Sep 30, 2010

A PHASE3 clinical study on Infections, Papillomavirus, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 8 data snapshots since 2009. Infectious disease trials contribute critical data for public health response and treatment development.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE3

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE3

  5. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE3

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

May 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Hong Kong, Hong Kong